Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 51:1938-1943, doi:10.1016/j.jacc.2007.12.054
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shah, S. J.
Right arrow Articles by LaRosa, J. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shah, S. J.
Right arrow Articles by LaRosa, J. C.
Related Collections
Right arrowRelated Article

Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery

Sanjiv J. Shah, MD*,{dagger}, David D. Waters, MD*,*, Philip Barter, MD{ddagger}, John J.P. Kastelein, MD, PhD§, James Shepherd, MD||, Nanette K. Wenger, MD, David A. DeMicco, DPharm#, Andrei Breazna, PhD# and John C. LaRosa, MD**

* Division of Cardiology, San Francisco General Hospital, and the Department of Medicine, University of California, San Francisco, California
{dagger} Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois
{ddagger} Heart Research Institute, Sydney, Australia
§ Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
|| University of Glasgow, Glasgow, United Kingdom
Emory University School of Medicine, Atlanta, Georgia
# Pfizer Inc., New York, New York
** State University of New York Health Science Center, New York, New York.


Figure 1
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Kaplan-Meier Curves for a Primary End-Point Event in Patients With and Without Prior CABG

Primary end points were cardiac death, myocardial infarction, resuscitated cardiac arrest, and stroke. CABG = coronary artery bypass graft surgery; CI = confidence interval; HR = hazard ratio.

 

Figure 2
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Kaplan-Meier Curves for the Primary End Point Among Patients With Prior CABG

Abbreviations as in Figure 1.

 

Figure 3
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Kaplan-Meier Curves for Coronary Revascularization Among Patients With Prior CABG

Revascularization was either repeat CABG or percutaneous coronary intervention, in the 80- and 10-mg atorvastatin groups among patients with prior CABG at baseline. Abbreviations as in Figure 1.

 

Figure 4
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4 Kaplan-Meier Curves for a Combination of the Primary End Point or for Coronary Revascularization

Abbreviations as in Figure 1.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement